Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts
Year: 2020
Type: article
Abstract: Recent studies demonstrate that addition of neoadjuvant (NA) carboplatin (Cb) to anthracycline/taxane chemotherapy improves pathological complete response (pCR) in triple negative breast cancer (TNBC). Effectiveness of anthracycline-free, platinum combinations in TNBC is not well known. Here we report efficacy of NA carboplatin + docetaxel (CbD) in TNBC.
DOI: 10.17615/pmme-tn03
Authors: Picornell, Antoni C., Cortes, Javier, Sharma, Priyanka, Palomero, María Isabel, Gonzalez-Rivera, Milagros, Amin, Amanda L., Mammen, Joshua M.V., Morales, Denisse Bretel, García-Saenz, Jose Angel, Massarrah, Tatiana, Del Monte-Millán, Maria, Ward, Claire, Wagner, Jamie L., Jerez-Gilarranz, Yolanda, Klemp, Jennifer R., López-Tarruella, Sara, Connor, Carol S., Prat, Aleix, Gómez, Henry L., Heldstab, Jaimie, Jensen, Roy A., McGinness, Marilee K., Fabian, Carol J., Martin, Miguel, Kimler, Bruce F., González Del Val, Ricardo, Márquez-Rodas, Iván, Pelaez-Lorenzo, Beatriz, Khan, Qamar J., Barnadas, Augusti, Rivera, Hugo Fuentes, Moreno, Fernando, Perou, Charles M., Godwin, Andrew K.
Institution: University of North Carolina at Chapel Hill
Language: English
Subfield: Cancer Research
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W4299812089